Merck to Present Data on Rebif® (interferon beta-1a) and Cladribine Tablets for Multiple Sclerosis at 2nd Congress of the European Academy of Neurology - Seite 2

Location: Screen F1

Abstract 1137; May 30, 2016, 12:30-13:15

Interim Analysis of the Non-Interventional Study REBIFLECT:
Adherence to Subcutaneous Interferon ?-1a in Patients Using
RebiSmart®-Logged Data and Their Reflection in Doctor-Patient
Interviews; P. Rieckmann

Location: Screen F2

Abstract 616; May 30, 2016, 12:30-13:15

Observational, Retrospective Study to Characterize Patients with
RRMS and Long-Term Treatment with SC Interferon (IFN) Beta 1-a; J.R.
Ara

Location: Screen F1

Abstract 657; May 30, 2016, 13:30-14:15

Reasons for Subcutaneous Interferon Beta-1a Three Times a Week
Discontinuation Among Patients with Multiple Sclerosis: a Real-World
Retrospective Cohort Study; M. Sabidó-Espin

Location: Screen F2

Abstract 1380; May 30, 2016, 12:30-13:15

A Retrospective Analysis of Efficacy in McDonald 2010 Multiple
Sclerosis (MS) Patients in the ORACLE-MS Study; M.S. Freedman

Location: Screen F1

Abstract 1105; May 29, 2016, 13:30-14:15

Effect of Cladribine Tablets on Brain Atrophy Rates in Patients
with Relapsing-Remitting Multiple Sclerosis (RRMS): Exploratory
Analysis of the CLARITY Study; N. de Stefano

Location: Screen F1

Abstract 1209; May 29, 2016, 12:30-13:15

Safety and Tolerability of Cladribine Tablets Added to IFN-Beta
Therapy in Patients with Active Relapsing Multiple Sclerosis: Final
Results from the ONWARD Study (Amended Protocol); X. Montalban

Location: Screen F2

Learn more about Merck's programs, pipeline and activities in
neurology by visiting our booth at this year's congress.

About Cladribine Tablets

Cladribine Tablets is an oral small molecule that targets the
immune cells thought to be integral to the pathological process of
MS. Cladribine Tablets is currently under clinical investigation and
not approved for any use in the United States, Canada and Europe.

About Rebif®

Rebif® (interferon beta-1a) is a disease-modifying drug used to
treat relapsing forms of multiple sclerosis (MS) and is similar to
the interferon beta protein produced by the human body. The efficacy
of Rebif® in chronic progressive MS has not been established.
Interferon ß is thought to help reduce inflammation. The exact
mechanism is unknown.

Rebif®, which was approved in Europe in 1998 and in the US in
2002, is registered in more than 90 countries worldwide. Rebif® has
been proven to delay the progression of disability, reduce the
frequency of relapses and reduce MRI lesion activity and area*.

Rebif® can be administrated with the RebiSmart® electronic
auto-injection device (not approved in the US), or with the RebiDose®